Prime Medicine is using the latest CRISPR technology to bring gene editing to patients. Prime editing is an innovative new approach to achieve precision genome editing without inducing double-stranded breaks. This enables safer and more efficient editing and has the potential to address more than 90% of known disease-causing mutations. Prime Medicine is using this “search and replace” tool to restore normal genetic function to almost anywhere in the genome. To develop their pipeline, Prime is working with Beam Therapeutics to enhance therapeutic delivery and manufacturing. 

<p>Prime Medicine is using the latest CRISPR technology to bring gene editing to patients. Prime editing is an innovative new approach to achieve precision genome editing without inducing double-stranded breaks. This enables safer and more efficient editing and has the potential to address more than 90% of known disease-causing mutations. Prime Medicine is using this “search and replace” tool to restore normal genetic function to almost anywhere in the genome. To develop their pipeline, Prime is working with Beam Therapeutics to enhance therapeutic delivery and manufacturing. </p>


Prime Medicine

Scientist II/Senior Scientist I, Analytical Development/Early QC-Molecular

Scientist I/II, Analytical Development

Scientist/Senior Scientist, Oligonucleotide Chemistry

 Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics 

www.primemedicine.com

 Prime Medicine down 5%, prices $140M stock offering 

 With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors 

 Chardan Capital Maintains Buy on Prime Medici... 

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb - MarketWatch

We are excited to present in vivo proof-of-concept data highlighting interim preclinical advances in our #WilsonsDisease program and the broad potential of our universal liver-targeted LNP at #ESGCT2024. The data demonstrated successful correction of disease-causing mutations in Wilson’s Disease in both mouse and non-human primate (NHP) models. Additionally, we highlighted the ability of our universal liver-targeted LNP platform to deliver Prime Editors to correct the underlying mutational cause of Glycogen Storage Disease Type 1b (#GSD1b) in humanized mice and NHPs, reinforcing the potential for our modular LNP to support future programs in rare and non-rare liver indications. CSO Jeremy Duffield comments on these promising findings below. Learn more in the press release. https://lnkd.in/eG2t77zG

Prime Medicine (NYSE:PRME) Stock Rating Upgraded by Citizens Jmp - MarketBeat

Prime Medicine Reports Q3 2024 Financial Progress - TipRanks


												12_9_21
												Nature Biotechnology												Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing
												Andrew V. Anzalone, Xin D. Gao, Christopher J. Podracky, Andrew T. Nelson, Luke W. Koblan, Aditya Raguram, Jonathan M. Levy, Jaron A.M. Mercer & David R. Liu											

 Prime Medicine reports Q3 EPS (44c), consensus (44c) 


												8_31_23
												Cell												Phage-assisted evolution and protein engineering yield compact, efficient prime editors
												Jordan L. Doman, Smriti Pandey, Monica E. Neugebauer, Meirui An, Jessie R. Davis, Peyton B. Randolph, Amber McElroy, Xin D. Gao, Aditya Raguram, Michelle F. Richter, Kelcee A. Everette, Samagya Banskota, Kathryn Tian, Y Allen Tao, Jakub Tolar, Mark J. Osborn & David R. Liu											

The achievements of Prime Medicine would not be possible without the dedication and resilience of everyone who has been a part of our journey. Their dedication to making next-generation medicines a reality for patients drives our mission forward each day. We are grateful for the advancements we made in 2024, and look forward to continuing to work towards impacting patients & families in 2025. Cheers!

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance

Fmr LLC Sells 184,541 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat

 Prime Medicine 19.2M share Spot Secondary priced at $6.25 

 Prime Medicine assumed with a Buy at JonesResearch 

 Prime editing comes of age as FDA clears human trials 


						11_12_24
						Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
					

PKU in mice treated with base and prime editing

 Is prime editing ready for prime time? 

 Prime Medicine to Present at Upcoming Investor Conferences 

The FDA Has Cleared the First Clinical Trial Application for a Prime Editor - CRISPR Medicine News

Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat

 Prime Medicine GAAP EPS of -$0.44 beats by $0.03, revenue of $0.59M misses by $0.32M 

 Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to ... 

Prime Medicine initiated with an Outperform at JMP Securities - MSN

Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline - Genetic Engineering & Biotechnology News

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress - GlobeNewswire

Prime Medicine lays off workers as it trims pipeline - STAT

We are pleased to announce we will highlight advances from across our Prime Editing pipeline and platform at the upcoming #ESGCT2024 and #TLM24 meetings. CSO Jeremy Duffield shares insight into these exciting preclinical data, especially from our #WilsonsDisease program. Find full presentation details here. https://lnkd.in/eCivDhyV

Cambridge's East End House uses a holistic approach to promote the well-being, academic achievement, and successful transition to adulthood of local youth from under-resourced families. Prime team members recently spent an afternoon volunteering in EEH's food pantry department to help serve our neighbors in need. We are grateful for opportunities to make an impact in our local Kendall Square community. 

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Prime CTO Ann Lee will join Georgia Tech Research at their upcoming Immunoengineering Industry Symposium to give a keynote presentation on Prime Editing. Learn more about Friday's event here. https://lnkd.in/e5Xh-MtC

Wilson Sonsini Advises Prime Medicine on IP Matters Related to Upsized Public Offering - Wilson Sonsini

10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey

Prime Medicine to Highlight New Preclinical Data, Including - GlobeNewswire


						10_24_24
						Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
					


												4_17_23
												Nature Biomedical Engineering												Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice
												Kelcee A. Everette, Gregory A. Newby, Rachel M. Levine, Kalin Mayberry, Yoonjeong Jang, Thiyagaraj Mayuranathan, Nikitha Nimmagadda, Erin Dempsey, Yichao Li, Senthil Velan Bhoopalan, Xiong Liu, Jessie R. Davis, Andrew T. Nelson, Peter J. Chen, Alexander A. Sousa, Yong Cheng, John F. Tisdale, Mitchell J. Weiss, Jonathan S. Yen & David R. Liu											

Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb - MedCity News

 Prime Medicine just upgraded at Citi, here's why 


						11_6_24
						Prime Medicine to Participate in Upcoming Investor Conferences
					

 Prime Medicine GAAP EPS of -$0.46 misses by $0.05 

ASGCT24: Prime Medicine to Apply Gene Editing to Wide-Ranging Indications - BioSpace

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? - Yahoo Finance

 Gene-editing firm Prime Medicine files $140m public offer 


												10_14_21
												cell												Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
												Peter J. Chen, Jeffrey A. Hussmann, Jun Yan, Friederike Knipping, Purnima Ravisankar,
Pin-Fang Chen, Cidi Chen, James W. Nelson, Gregory A. Newby, Mustafa Sahin,
Mark J. Osborn, Jonathan S. Weissman, Britt Adamson & David R. Liu											

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday - The Motley Fool

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique - BioSpace

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace

 Market Update: 

Prime Medicine uncloaks with $315M to push 'search and ...

We're headed to San Diego this week for #ASH24, where Associate Director Jack Heath will share research demonstrating that Prime Editing can potentially be used to develop shielded HSCs that can be used in combination with antibody-based conditions regimens, eliminating the need for toxic chemotherapy regimens prior to transplantation. Read the full abstract here. https://lnkd.in/ejjhGAsg

Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? - Yahoo Finance


												1_8_24
												Nature Biotechnology												Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo
												Meirui An, Aditya Raguram, Samuel W. Du, Samagya Banskota, Jessie R. Davis, Gregory A. Newby, Paul Z. Chen, Krzysztof Palczewski & David R. Liu											

 Prime Medicine GAAP EPS of -$2.18 

Updated: Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers - Endpoints News

Prime Medicine shares rise on $3.5 billion BMS collaboration - Investing.com

 Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably ... 

The biotech news you need to read today - STAT

 Crude Oil Moves Higher; Prime Medicine Shares Spike Higher 

PRIME: priority medicines - European Medicines Agency |

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates - Yahoo Finance

BMS Inserts Cash Into Prime Medicine’s Gene-Editing Ambitions - Citeline News & Insights

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) - GlobeNewswire

Prime gets FDA green light to begin first trial test of ‘prime editing’ - BioPharma Dive

Prime Medicine (NYSE:PRME) Now Covered by Analysts at JMP Securities - MarketBeat

 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates 

Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News

 Prime Medicine upgraded at Citi on valuation, pipeline 

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies - GlobeNewswire

FDA Clears Prime Medicine’s IND for First Prime Editing Therapy - Genetic Engineering & Biotechnology News

A radiopharmaceuticals startup raises $175 million - STAT

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Yahoo Finance

New prime editor delivery particles help restore vision in mice

Prime Medicine soars as it inks research collab with BMS - The Pharma Letter

 Bristol, Prime Medicine in deal to develop T-cell therapies 

 Why Prime Medicine Stock Soared Nearly 12% Higher on Monday 

 Prime Medicine stock falls on proposed public offering of common stock 

PRME Stock Rises 11.8% on Collaboration With Bristol Myers - Yahoo Finance

 Prime Medicine to Participate in Upcoming Investor Conferences 

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

 Prime Medicine initiated with bullish view at JMP Securities, here's why 

More beef in the gene editing space - STAT

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Benzinga

Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance


												10_19_19
												nature												Search-and-replace genome editing without double-strand breaks or donor DNA
												Andrew V. Anzalone, Peyton B. Randolph, Jessie R. Davis, Alexander A. Sousa, Luke W. Koblan, Jonathan M. Levy, Peter J. Chen, Christopher Wilson, Gregory A. Newby, Aditya Raguram & David R. Liu											

 Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming ... 

Prime Medicine gets green light for trials of first-ever prime editing drug - Clinical Trials Arena

We recently held our annual team Thanksgiving celebration! We use this time as an opportunity to gather together, enjoy a delicious potluck and express gratitude and appreciation for the strides we've made in 2024 towards delivering transformative medicines to patients. Wishing everyone a happy and restful Thanksgiving with their loved ones.

 Prime Medicine Gets FDA Clearance for PM359 IND Application 

 Form 424B5 Prime Medicine, Inc. 

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha

Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com

 Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley 

#WilsonDisease currently has no cure and requires lifelong treatment. Today, on #WilsonDiseaseAwarenessDay, we stand with those whose lives have been upended by this disease, and are proud to be working to offer improved treatment options to those in need. #WilsonDiseaseAwareness

 FDA clears Prime Medicine to begin gene therapy clinical testing 

Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire

Prime Medicine

Business:

About: